PTC596 structure
|
Common Name | PTC596 | ||
|---|---|---|---|---|
| CAS Number | 1610964-64-1 | Molecular Weight | 420.339 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 583.9±60.0 °C at 760 mmHg | |
| Molecular Formula | C19H13F5N6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 307.0±32.9 °C | |
Use of PTC596PTC596 is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. PTC596 targets BMI1 expressed by both tumor cells and cancer stem cells (CSCs), and induces hyper-phosphorylation of BMI1, leading to its degradation. PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells[1][2]. |
| Name | 5-Fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]-4,6-pyrimidinediamine |
|---|---|
| Synonym | More Synonyms |
| Description | PTC596 is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. PTC596 targets BMI1 expressed by both tumor cells and cancer stem cells (CSCs), and induces hyper-phosphorylation of BMI1, leading to its degradation. PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells[1][2]. |
|---|---|
| Related Catalog | |
| Target |
BMI-1[1] |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 583.9±60.0 °C at 760 mmHg |
| Molecular Formula | C19H13F5N6 |
| Molecular Weight | 420.339 |
| Flash Point | 307.0±32.9 °C |
| Exact Mass | 420.112183 |
| LogP | 3.68 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.645 |
| 5-Fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]-4,6-pyrimidinediamine |
| 4,6-Pyrimidinediamine, 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N4-[4-(trifluoromethyl)phenyl]- |